(702) 683-8946

Monday - Friday 9am to 5pm

triangle
ad1

http://crweworld.com/assets/images/ad/buy_a_domain.png

Buy and register domain names online from CRWE Domains. Web hosting, spam-free email, web marketing, secure SSL Certificates and more

www.crwedomains.com

ad2

http://crweworld.com/assets/images/ad/ad4.png

Place Your Ad Here! Advertise your business online on CRWE WORLD. Your Company, product, or service in front of the world!

Contact Us: contact@crweworld.com

www.CRWEWorld.com

ad3

http://crweworld.com/assets/img/crwe_info.png

CRWE Info ( CRWE.Info ) provides news and updates about Crown Equity Holdings Inc. and the CRWE World platform

www.crwe.info

ad4

http://crweworld.com/assets/images/ad/submit_a_press_release.jpg

Submit Your Press Release/News to the CRWE WORLD Network for $14.95! Increase Visibility, Boost Your Business

www.CRWEPressRelease.com

ad5

http://crweworld.com/assets/images/ad/Pathology_Laboratories.png

Quest Diagnostics Inc. (NYSE:DGX) offers the most extensive clinical testing network in the U.S. The Company's extensive test menu includes routine biological testing; complex and specialized molecular and gene-based testing, and anatomic pathology testing. These services primarily help identify disease or risk factors for disease and predict and monitor response to treatment.

www.QuestDiagnostics.com






11 Result: Puma Biotechnology

Puma Biotechnology Announces European Medicines Agency Validation of Marketing Authorization Application for PB272 (Neratinib) as Extended Adjuvant Treatment of HER2-Positive Early Stage Breast Cancer in Europe

August 22nd, 2016

LOS ANGELES, Calif. / CRWE PRESS RELEASE / August 22, 2016 - Puma Biotechnology, Inc. (NYSE: PBYI), a biopharmaceutical company, announced that the Marketing Authorization Application (MAA) for neratinib has been validated by the European Medicines A. Read more

Puma Biotechnology Announces Interim 5-Year Disease Free Survival Data from Phase III Trial of PB272 (Neratinib) in Extended Adjuvant HER2-Positive Early Stage Breast Cancer (ExteNET Trial)

July 21st, 2016

LOS ANGELES, Calif. / CRWE PRESS RELEASE / July 21, 2016 - Puma Biotechnology, Inc. (NYSE: PBYI), a biopharmaceutical company, announced updated results from the Phase III clinical trial of Puma's investigational drug PB272 (neratinib) for t. Read more

Puma Biotechnology Submits New Drug Application for PB272 (Neratinib) to U.S. FDA for Extended Adjuvant Treatment of HER2-Positive Early Stage Breast Cancer

July 21st, 2016

LOS ANGELES, Calif. / CRWE PRESS RELEASE / July 21, 2016 - Puma Biotechnology, Inc. (NYSE: PBYI), a biopharmaceutical company, has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for its lead product candida. Read more

Puma Biotechnology Presents Positive Phase II Data at the 2016 ASCO Annual Meeting

June 05th, 2016

LOS ANGELES, Calif. / CRWE PRESS RELEASE / June 5, 2016 - Puma Biotechnology, Inc. (NYSE: PBYI), a biopharmaceutical company, presented positive results from an investigator sponsored Phase II trial of neratinib with HER2-mutated, non-amplified . Read more

Puma Biotechnology Announces the Conclusion and Final Results of Eshelman's Consent Solicitation

February 16th, 2016

LOS ANGELES, Calif. / CRWEPRESSRELEASE / February 16, 2016 - Puma Biotechnology, Inc. (NYSE: PBYI), a biopharmaceutical company, announced that the deadline for Fredric Eshelman to deliver the requisite consents expired on February 15, 2016, and. Read more

Puma Biotechnology Shareholders Overwhelmingly Reject Eshelman's Consent Solicitation

January 08th, 2016

LOS ANGELES, Calif. / CRWEPRESSRELEASE / January 8, 2016 – Puma Biotechnology, Inc. (NYSE: PBYI), a biopharmaceutical company, announced that shareholders representing over 80% of the Company’s shares outstanding have rejected the proposa. Read more

Puma Biotechnology Provides Update from Meeting with European Medicines Agency

November 30th, 2015

LOS ANGELES, Calif. / CRWEPRESSRELEASE / November 30, 2015 - Puma Biotechnology, Inc. (NYSE: PBYI), a biopharmaceutical company, announced that based on its recent meeting with the European Medicines Agency (EMA), the Company plans to submit a M. Read more

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Puma Biotechnology, Inc. - PBYI

May 01st, 2015

NEW YORK, NY / CRWEPRESSRELEASE / May 1, 2015 / Pomerantz LLP is investigating claims on behalf of investors of Puma Biotechnology, Inc. ("Puma" or the "Company") (NYSE: PBYI). Such investors are advised to contact Robert S. Willoughby at rswilloughb. Read more

CEL-SCI is a Rare Value Opportunity in Cancer Immunotherapy Stocks

April 23rd, 2015

NEW YORK, NY / CRWEPRESSRELEASE / April 23, 2015 / Cancer immunotherapy is scorching hot. At no time in medical history has a new cancer treatment been so widely researched and highly paid for. Over the last 50 years, the only medicine for cancer has. Read more

Cel-Sci's Cancer Immunotherapy In Phase III Is Value Opportunity

March 12th, 2015

BALTIMORE, MD / CRWEPRESSRELEASE / March 12, 2015 / Cancer immunotherapy has become today's word for treating patients with death-causing diseases, but progress and valuations within companies run a broad course. In this article, I will explain to in. Read more

Puma Biotechnology Reports Positive Top Line Data from I-SPY 2 TRIAL

December 04th, 2013

Neratinib Graduates from I-SPY 2 TRIAL LOS ANGELES, Calif., Dec. 4, 2013 - (CRWE Press Release) - Puma Biotechnology, Inc. (NYSE: PBYI), a development stage biopharmaceutical company, today announced top line results from the Phase II clinical tri. Read more

Load More Content